Founded in 2006, KingSung Medical Group takes "making surgery simpler and life better" as its mission, and adheres to the long-term development goal of " Profession-oriented, innovation-driven, becoming a leader in the global medical subdivision field ". It has now evolved into a high-tech medical conglomerate integrating production, research, and sales. The company has been honored with titles such as "National High-Tech Enterprise," "Specialized and New Enterprise," and "Tianjin Strategic Emerging Industry Leading Enterprise" by the government. It currently serves as the Executive Deputy Chairman unit of the Microsurgery Branch of the China Medical Device Industry Association and is a member of the China Society for Biomaterials.
Since its inception, the group has been focused on "addressing clinical pain points and patient needs," dedicated to providing exclusive and innovative solutions for surgical fields such as microsurgery. We rely on four major research and development technology platforms—vascular anastomosis technology platform, polymer material technology platform, magnesium alloy material technology platform, and biomaterial technology platform—to carry out a series of advanced technology development and research projects. We work closely with domestic and international universities, research institutions, and clinical experts to conduct scientific research projects. To date, we have obtained 145 patents, nearly 50 of which are invention patents, and have launched several internationally leading or original products, with multiple product technologies reaching international advanced levels.
The group currently consists of five companies: Huarong KingSung Biotechnology (Tianjin) Co., Ltd., which includes subsidiaries Chuangmeide Medical Devices (Tianjin) Co., Ltd., Huarong KingSung Biotechnology (Beijing) Co., Ltd., KingSung Medical Biotechnology (Hong Kong) Co., Ltd., and KingSung Yunxuehui (Beijing) Consulting Services Company, with a total registered capital of 100 million yuan.
中文
English